CoChat

PCSK9 R46L Loss-of-Function Mutation Reduces Lipoprotein(a), LDL Cholesterol, and Risk of Aortic Valve Stenosis

Open access
Langsted, Anne, Nordestgaard, Børge G., Benn, Marianne, Tybjærg-Hansen, Anne, Kamstrup, Pia R. · 2016 · The Journal of Clinical Endocrinology & Metabolism

The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.

Abstract

Context: Novel, low-density lipoprotein (LDL) cholesterol-lowering proprotein convertase subtilisin/kexin type-9 (PCSK9) inhibitors also lower lipoprotein(a) levels, but the effect on aortic valve stenosis and myocardial infarction is unknown. Objective: We tested the hypothesis that the PCSK9 R46L loss-of-function mutation is associated with lower levels of lipoprotein(a) and with reduced risk of aortic valve stenosis and myocardial infarction. Design: We used two prospective cohort studies of the general population and one patient-based cohort. Setting: Cohort studies selected at random individuals of Danish descent. Participants: We studied 103 083 individuals from the Copenhagen General Population Study, the Copenhagen City Heart Study, and the Copenhagen Ischemic Heart Disease Study. Main outcome measures: Lipoprotein(a), LDL cholesterol, and PCSK9 R46L genotype and diagnoses of aortic valve stenosis and myocardial infarction from national registries; lipoprotein(a) was measured from 49,617 individuals. Results: Median (interquartile range) lipoprotein(a) levels were 10 (5–30) mg/dl for PCSK9 R46L noncarriers, 9 (4–32) mg/dl for heterozygotes, and 8 (4–42) mg/dl for homozygotes (trend P = .02). The corresponding values for LDL cholesterol levels were 124 (101–147) mg/dl, 104 (85–132) mg/dl, and 97 (85–128) mg/dl, respectively (trend P = 2 × 10−52). PCSK9 R46L carriers vs noncarriers had an age- and sex-adjusted odds ratio of 0.64 (95% confidence interval, 0.44–0.95) for aortic valve stenosis, 0.77 (0.65–0.92) for myocardial infarction, and 0.76 (0.64–0.89) for aortic valve stenosis or myocardial infarction. Conclusions: PCSK9 R46L carriers have lower levels of lipoprotein(a) and LDL cholesterol as well as reduced risk of aortic valve stenosis and myocardial infarction. This indirectly suggests that PCSK9 inhibitors may have a role in patients with aortic valve stenosis.

Overview

Integrity signals

Registry

Crossref · 10.1210/jc.2016-1206

Cites

33 of 33 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

The text we found for this paper looks like another document, so its claims and self-check weren’t run. The registry and citation checks still apply.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The text we found for this paper looks like another document, so the self-check wasn’t run.

Citations

Cites

Research works printed but not linked: 1

  1. Utermann, 2001, Lipoprotein(a), 2753

Cited by

See all 138

Metadata

Authors
Langsted, A., Nordestgaard, B. G., Benn, M., Tybjærg-Hansen, A., & Kamstrup, P. R.
Affiliations
  • University of Copenhagen (DK)
  • Frederiksberg Hospital (DK)
  • The Copenhagen General Population Study (A.L., B.G.N., M.B., A.T.-H., P.R.K.), Herlev and Gentofte Hospital, Copenhagen University Hospital, Copenhagen, Denmark
Corresponding author
Kamstrup, Pia R.
Venue
The Journal of Clinical Endocrinology & Metabolism
Published
2016-05-24
Volume
101
Issue
9
Pages
3281-3287
ISSN
  • 0021-972X (ISSN-L)
  • 1945-7197
OpenAlex
W2404696858
Cited by
136
References
33
Citations by year
2026: 12 · 2025: 13 · 2024: 20 · 2023: 17 · 2022: 13 · 2021: 14 · 2020: 13 · 2019: 9 · 2018: 15 · 2017: 8 · 2016: 1
FWCI
12.19
Type
journal article
Language
en
Open access
Licence
other-oa
Locations
  • The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
  • PubMed (publishedVersion)
  • Research at the University of Copenhagen (University of Copenhagen) (publishedVersion, other-oa)
Funders
  • Eli Lilly and Company
  • Sanofi
  • Fresenius Medical Care North America
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
Keywords
PCSK9, loss-of-function mutations, lipoprotein(a), LDL cholesterol, aortic stenosis, myocardial infarction, PCSK9 inhibitors, genetic association, cardiovascular risk, hypercholesterolemia, familial hypercholesterolemia, cardiovascular disease prevention, Danish population, Copenhagen General Population Study, Copenhagen City Heart Study
MeSH terms
Proprotein Convertase 9, Adult, Aged, Aged, 80 and over, Aortic Valve Stenosis, Female, Follow-Up Studies, Genotype, Heterozygote, Humans, Cholesterol, LDL, Male, Middle Aged, Mutation, Myocardial Infarction, Prognosis, Prospective Studies, Risk Factors, Biomarkers, Lipoprotein(a), Genetic Predisposition to Disease, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.